KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Net Margin (2016 - 2025)

West Pharmaceutical Services' Net Margin history spans 17 years, with the latest figure at 15.93% for Q4 2025.

  • For Q4 2025, Net Margin fell 118.0% year-over-year to 15.93%; the TTM value through Dec 2025 reached 15.59%, down 93.0%, while the annual FY2025 figure was 15.59%, 93.0% down from the prior year.
  • Net Margin for Q4 2025 was 15.93% at West Pharmaceutical Services, down from 17.14% in the prior quarter.
  • Across five years, Net Margin topped out at 24.7% in Q2 2021 and bottomed at 12.38% in Q1 2025.
  • The 5-year median for Net Margin is 17.98% (2023), against an average of 18.72%.
  • The largest annual shift saw Net Margin surged 996bps in 2021 before it crashed -708bps in 2022.
  • A 5-year view of Net Margin shows it stood at 20.21% in 2021, then crashed by -30bps to 14.08% in 2022, then rose by 30bps to 18.27% in 2023, then decreased by -6bps to 17.11% in 2024, then fell by -7bps to 15.93% in 2025.
  • Per Business Quant, the three most recent readings for WST's Net Margin are 15.93% (Q4 2025), 17.14% (Q3 2025), and 16.54% (Q2 2025).